Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS

Phase 1/2 Active not recruiting 55 enrolled Dana-Farber Cancer Institute Secura Bio, Inc. · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This research study is assessing a new drug, duvelisib, in combination with a drug that is already FDA approved, venetoclax, as a possible treatment for participants with CLL or those with Richter's Syndrome

Timeline

Start: 2018-07-12
Primary completion: 2024-12-01
Completion: 2026-07-01

Publications

Crombie JL, Ryan CE, Ren Y, Tyekucheva S, Carey C, Zou A, Normilus S, Montegaard J, Bhandari S, Alencar A, Soumerai JD, Arnason JE, Kim AI, Parry EM, Armand P, Fisher DC, Brown JR, Davids MS. A phase 1/2 study of duvelisib plus venetoclax in patients with relapsed/refractory CLL/SLL or Richter transformation. Blood Adv. 2026 Jun 9;10(11):3811-3819. doi: 10.1182/bloodadvances.2025018878.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Duvelisib	Small molecule	25 mg	Oral
Subject	Venetoclax	Small molecule	100 mg	Oral
Subject	Venetoclax	Small molecule	200 mg	Oral
Subject	Venetoclax	Small molecule	400 mg	Oral

Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS

Summary

Timeline

Publications

Drugs

Indications